Abstract
We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginterferon (PEG-IFN) α-2a or conventional IFN α-2a would improve sustained virological response (SVR) rates over dual therapy with IFN α-2a and RBV in patients with chronic HCV infection. A total of 362 treatment-naïve patients were randomized to 48 weeks of treatment with: PEG-IFN α-2a 180 μg/week (group A) or IFN α-2a 3 MU tiw (groups B and C). All patients received RBV 1000 or 1200 mg/day and those in groups A and B received AMA 200 mg/day, SVR was defined as an undetectable HCV RNA after 24 weeks of untreated follow-up. At the end of therapy, 74.4% (95% CI 0.66-0.82) of patients in group A were HCV RNA-negative compared with 42.5% (95% CI 0.33-0.50) of those in group B(P = 0.0001) and 48.8% (95% CI 0.40-0.56) of those in group C. SVR was achieved in a significantly greater proportion of patients in group A compared with groups B and C: 65.3% (95% CI 0.53-0.56), 33.3% (95% CI 0.25-0.41) and 44.6% (95% CI 0.36-0.53; P = 0.0001) respectively. In patients with genotype 1. SVR rates were 55.2, 22.8 and 28.8% with the three regimens respectively. Factors independently associated with SVR were HCV genotype 2 or 3, therapy with PEG-IFN, female gender and age. In treatment-naïve patients with chronic hepatitis C, triple therapy with PEG-IFN α-2a. RBV and AMA produces higher SVR than dual or triple therapy with conventional IFN α-2a.
| Original language | English |
|---|---|
| Pages (from-to) | 292-299 |
| Number of pages | 8 |
| Journal | Journal of Viral Hepatitis |
| Volume | 12 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - May 2005 |
Fingerprint
Keywords
- Amantadine
- Chronic hepatitis C
- Interferon α-2a
- Peginterferon α-2a
- Ribavirin
- Therapy
ASJC Scopus subject areas
- Hepatology
- Virology
Cite this
A randomized controlled trial of pegylated interferon α-2a (40 KD) or interferon α-2a plus ribavirin and amantadine vs interferon α-2a and ribavirin in treatment-naïve patients with chronic hepatitis C. / Mangia, A.; Ricci, G. L.; Persico, M.; Minerva, N.; Carretta, V.; Bacca, D.; Cela, M.; Piattelli, M.; Annese, M.; Maio, G.; Conte, D.; Guadagnino, V.; Pazienza, V.; Festi, D.; Spirito, F.; Andriulli, A.
In: Journal of Viral Hepatitis, Vol. 12, No. 3, 05.2005, p. 292-299.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A randomized controlled trial of pegylated interferon α-2a (40 KD) or interferon α-2a plus ribavirin and amantadine vs interferon α-2a and ribavirin in treatment-naïve patients with chronic hepatitis C
AU - Mangia, A.
AU - Ricci, G. L.
AU - Persico, M.
AU - Minerva, N.
AU - Carretta, V.
AU - Bacca, D.
AU - Cela, M.
AU - Piattelli, M.
AU - Annese, M.
AU - Maio, G.
AU - Conte, D.
AU - Guadagnino, V.
AU - Pazienza, V.
AU - Festi, D.
AU - Spirito, F.
AU - Andriulli, A.
PY - 2005/5
Y1 - 2005/5
N2 - We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginterferon (PEG-IFN) α-2a or conventional IFN α-2a would improve sustained virological response (SVR) rates over dual therapy with IFN α-2a and RBV in patients with chronic HCV infection. A total of 362 treatment-naïve patients were randomized to 48 weeks of treatment with: PEG-IFN α-2a 180 μg/week (group A) or IFN α-2a 3 MU tiw (groups B and C). All patients received RBV 1000 or 1200 mg/day and those in groups A and B received AMA 200 mg/day, SVR was defined as an undetectable HCV RNA after 24 weeks of untreated follow-up. At the end of therapy, 74.4% (95% CI 0.66-0.82) of patients in group A were HCV RNA-negative compared with 42.5% (95% CI 0.33-0.50) of those in group B(P = 0.0001) and 48.8% (95% CI 0.40-0.56) of those in group C. SVR was achieved in a significantly greater proportion of patients in group A compared with groups B and C: 65.3% (95% CI 0.53-0.56), 33.3% (95% CI 0.25-0.41) and 44.6% (95% CI 0.36-0.53; P = 0.0001) respectively. In patients with genotype 1. SVR rates were 55.2, 22.8 and 28.8% with the three regimens respectively. Factors independently associated with SVR were HCV genotype 2 or 3, therapy with PEG-IFN, female gender and age. In treatment-naïve patients with chronic hepatitis C, triple therapy with PEG-IFN α-2a. RBV and AMA produces higher SVR than dual or triple therapy with conventional IFN α-2a.
AB - We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginterferon (PEG-IFN) α-2a or conventional IFN α-2a would improve sustained virological response (SVR) rates over dual therapy with IFN α-2a and RBV in patients with chronic HCV infection. A total of 362 treatment-naïve patients were randomized to 48 weeks of treatment with: PEG-IFN α-2a 180 μg/week (group A) or IFN α-2a 3 MU tiw (groups B and C). All patients received RBV 1000 or 1200 mg/day and those in groups A and B received AMA 200 mg/day, SVR was defined as an undetectable HCV RNA after 24 weeks of untreated follow-up. At the end of therapy, 74.4% (95% CI 0.66-0.82) of patients in group A were HCV RNA-negative compared with 42.5% (95% CI 0.33-0.50) of those in group B(P = 0.0001) and 48.8% (95% CI 0.40-0.56) of those in group C. SVR was achieved in a significantly greater proportion of patients in group A compared with groups B and C: 65.3% (95% CI 0.53-0.56), 33.3% (95% CI 0.25-0.41) and 44.6% (95% CI 0.36-0.53; P = 0.0001) respectively. In patients with genotype 1. SVR rates were 55.2, 22.8 and 28.8% with the three regimens respectively. Factors independently associated with SVR were HCV genotype 2 or 3, therapy with PEG-IFN, female gender and age. In treatment-naïve patients with chronic hepatitis C, triple therapy with PEG-IFN α-2a. RBV and AMA produces higher SVR than dual or triple therapy with conventional IFN α-2a.
KW - Amantadine
KW - Chronic hepatitis C
KW - Interferon α-2a
KW - Peginterferon α-2a
KW - Ribavirin
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=21044444857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=21044444857&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2893.2005.00591.x
DO - 10.1111/j.1365-2893.2005.00591.x
M3 - Article
C2 - 15850470
AN - SCOPUS:21044444857
VL - 12
SP - 292
EP - 299
JO - Journal of Viral Hepatitis
JF - Journal of Viral Hepatitis
SN - 1352-0504
IS - 3
ER -